Ann Arbor, MI: Most US patients registered to access medical cannabis cite chronic pain as their primary qualifying condition, according to data published in the journal Health Affairs.
Investigators from the University of Michigan, Ann Arbor reviewed patient registration data from the majority of states that provide medical cannabis access. (Some states, notably California and Maine, possess voluntary registries and therefore do not compile patient profile data.)
They reported that in 2016, chronic pain was the most common qualifying condition reported by patients (65 percent). They added, “Of all patient-reported qualifying conditions, 85 percent had either substantial or conclusive evidence of therapeutic efficacy,” as defined by the 2017 report published by the National Academy of Sciences, Engineering, and Medicine. The authors of that report concluded that there exists conclusive or substantial evidence for the effectiveness of cannabis in the treatment of chronic pain, nausea and vomiting, and spasticity.
Separate studies indicate that legal cannabis access is typically associated with reduced rates of opioid use and abuse. Studies have also identified a reduction in the prevalence of opioid-related mortality following statewide marijuana access.
Authors concluded: “[O]ur data show that the number of medical cannabis patients has risen dramatically over time as more states have legalized medical cannabis. … [W]e believe not only that it is inappropriate for cannabis to remain a Schedule I substance, but also that state and federal policy makers should begin evaluating evidence-based ways for safely integrating cannabis research and products into the health care system.”
For more information, contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, “Qualifying conditions of medical cannabis license holders in the United States,” appears in Health Affairs. Additional information is available in NORML’s fact-sheet, “Relationship Between Marijuana and Opioids.”